Leonardi M, Guastafierro E, Toppo C, D’Amico D (2023) Societal and personal impact of migraine. In: Handbook of clinical neurology. UOC Neurologia, Salute Pubblica, Disabilità, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy: Elsevier B.V,  p 23–9. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85178135976&doi=10.1016%2FB978-0-12-823356-6.00015-9&partnerID=40&md5=66d6034b338b737dae9200dc309295ef. Accessed 10 Apr 2025

Hamelsky SW, Stewart WF, Lipton RB (2007) Migraine. In: Handbook of clinical neuroepidemiology. Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, United States. Nova Science Publishers Inc, p 105–22. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84896416142&partnerID=40&md5=698149ba6bfdb69b9094db39ae88c03e. Accessed 10 Apr 2025

Cen J, Wang Q, Cheng L, Gao Q, Wang H, Sun F (2024) Global, regional, and national burden and trends of migraine among women of childbearing age from 1990 to 2021: insights from the global burden of disease study 2021. J Headache Pain 25(1). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85195438967anddoi=10.1186%2Fs10194-024-01798-zandpartnerID=40andmd5=808a16ebadbb4f38987bc2f16d1dae37. Accessed 10 Apr 2025

Victor T, Hu X, Campbell J, Buse D, Lipton R (2010) Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia 30(9):1065–72. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-77956569692anddoi=10.1177%2F0333102409355601andpartnerID=40andmd5=ecca6fef96e16a790c59bc18b33939bd. Accessed 10 Apr 2025

Afridi SK, Dassan P (2024) Special considerations in migraine during pregnancy and lactation. In: Handbook of clinical neurology [Internet]. Department of Neurology, Guy’s and St Thomas’ NHS Trust, London, United Kingdom: Elsevier B.V. p 257–63. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85183825477&doi=10.1016%2FB978-0-12-823357-3.00025-2&partnerID=40&md5=c5db09ca467b604155f2bc16b6246771. Accessed 10 Apr 2025

Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z (2020) Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain 21(1):4–7

Google Scholar 

Lu J-J, Zhao H-R (2022) Advances in the burden of migraine. Chinese J Contemp Neurol Neurosurg 22(2):69–72. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85126331331anddoi=10.3969%2Fj.issn.1672-6731.2022.02.002andpartnerID=40andmd5=a144cf22de97e6fdcda41cc4a546a739. Accessed 10 Apr 2025

Begasse de Dhaem O, Sakai F (2022) Migraine in the workplace. eNeurologicalSci  27. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85131782431&doi=10.1016%2Fj.ensci.2022.100408&partnerID=40&md5=a4960957dd30ac7424c6a7ab33012e04. Accessed 10 Apr 2025

Safiri S, Pourfathi H, Eagan A, Mansournia MA, Khodayari MT, Sullman MJM et al (2022) Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. Pain 163(2):E293–309. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85108986884anddoi=10.1097%2Fj.pain.0000000000002275andpartnerID=40andmd5=1b1083609758c456cd24a3c9eb2c82eb. Accessed 10 Apr 2025

Stovner LJ, Nichols E, Steiner TJ, Abd-Allah F, Abdelalim A, Al-Raddadi RM et al (2018) Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol 17(11):954–976.  https://www.scopus.com/inward/record.uri?eid=2-s2.0-85054876002anddoi=10.1016%2FS1474-4422%2818%2930322-3andpartnerID=40andmd5=0416b363ba784850e3c29a8ddb36dcbe. Accessed 10 Apr 2025

Versijpt J, Deligianni C, Hussain M, Amin F, Reuter U, Sanchez M (2024) European Headache Federation ( EHF ) critical re-appraisal and meta-analysis of oral drugs in migraine prevention - part 4 : propranolol. J Headache Pain 1–10. Available from: https://doi.org/10.1186/s10194-024-01826-y

Raffaelli B, Azorín DG, Boucherie DM, Amin FM, Deligianni CI, Gouveia RG et al (2023) European Headache Federation ( EHF ) critical reappraisal and meta - analysis of oral drugs in migraine prevention – part 3 : topiramate. J Headache Pain 1–13. https://doi.org/10.1186/s10194-023-01671-5

Deligianni CI, Sacco S, Ekizoglu E, Uluduz D, Gouveia RG, Maassenvandenbrink A, et al (2023) European Headache Federation ( EHF ) critical re - appraisal and meta - analysis of oral drugs in migraine prevention — part 2 : flunarizine. J Headache Pain 1–11. Available from: https://doi.org/10.1186/s10194-023-01657-3

Lampl C, Versijpt J, Amin FM, Deligianni CI, Gouveia RG, Jassal T et al (2023) European Headache Federation ( EHF ) critical re - appraisal and meta - analysis of oral drugs in migraine prevention — part 1 : amitriptyline. J Headache Pain 6:1–12. Available from: https://doi.org/10.1186/s10194-023-01573-6

Steiner TJ, Gouveia RG, Husøy AK, Jensen R, Katsarava Z, Martelletti P et al (2025) The Global Campaign against Headache, aged 21 : a critical self - appraisal, and plans for phase 2. J Headache 25–8. Available from: https://doi.org/10.1186/s10194-025-02003-5

Pellesi L, Jedie B, Barhum F, Al-Abdullah S, Martelletti P, Xiao Z (2025) Head-to-head relief: ubrogepant, rimegepant, and zavegepant in migraine treatment. Pain Manag 15(5):279–284. https://doi.org/10.1080/17581869.2025.2494494

Article  PubMed  Google Scholar 

Tana C, Raffaelli B, Nattan M, Souza P, Ruiz E, Torre D et al 2024 Health equity, care access and quality in headache – part 1, 7:1–12

Raffaelli B, Rubio-Beltrán E, Cho SJ, De Icco R, Labastida-Ramirez A (2023) Health equity, care access and quality in headache – part 2. J Headache Pain 1–14. Available from:https://doi.org/10.1186/s10194-023-01699-7

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, The PRISMA et al (2020) statement: an updated guideline for reporting systematic reviews. BMJ 2021:372

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C et al (2022) Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Clin Ther 44(2):158–168

PubMed  Google Scholar 

Johnston K, Powell LC, Popoff E, L’Italien GJ, Pawinski R, Ahern A et al (2024) Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK. J Med Econ 27(1):627–643. https://doi.org/10.1080/13696998.2024.2340932

Article  PubMed  Google Scholar 

Tian S, Yang Y, Tan S, Luo J, Yang C, Liu Q et al (2024) Cost-effectiveness analysis of rimegepant for on-demand acute treatment of migraine in China. Front Neurol 15(August):1–8

Google Scholar 

Thaliffdeen R, Yu A, Rascati K (2024) Cost-effectiveness evaluation of oral CGRP antagonists, atogepant and rimegepant, for the preventative treatment of episodic migraine: results from a US societal perspective model. Clin Drug Investig 44(3):209–217. https://doi.org/10.1007/s40261-024-01345-3

Article  CAS  PubMed  Google Scholar 

Mwamburi M, Tenaglia AT, Leibler EJ, Staats PS (2018) Cost-effectiveness of noninvasive vagus nerve stimulation for acute treatment of episodic migraine and role in treatment sequence strategies. Am J Manag Care 24(24):S527–S533

PubMed  Google Scholar 

Linde M, Timothy SJ, Chisholm D (2015) Cost-effectiveness analysis of interventions for migraine in four low- and middle-income countries. J Headache Pain 16:15. https://doi.org/10.1186/s10194-015-0496-6

Article  PubMed  PubMed Central  Google Scholar 

Griffin E, Shirley G, Lee XY, Awad SF, Tyagi A, Goadsby PJ (2024) An economic evaluation of eptinezumab for the preventive treatment of migraine in the UK, with consideration for natural history and work productivity. J Headache Pain 25(1):1–16. https://doi.org/10.1186/s10194-024-01749-8

Article  Google Scholar 

Mollaee H, Parashkouhi SN, Fatemi B, Seyedifar M, Soleymani F (2024) Cost-utility analysis of erenumab compared to topiramate for preventive therapy of migraine in Iran. Iran J Pharm Res 23(1):1–9

Google Scholar 

Nayak SK, Singh P, Panda AK, Mishra T, Sahu PK (2024) Cost-effective and cost-minimisation analysis of antiepileptic drugs in migraine patients at a tertiary care hospital in Bhubaneswar. Int Res J Multidiscip Scope 5(4):1006–1013

Google Scholar 

Pozo-Rosich P, Poveda JL, Crespo C, Martínez M, Rodríguez JM, Irimia P (2024) Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis. J Headache Pain 25(1):1–11. https://doi.org/10.1186/s10194-024-01747-w

Article  Google Scholar 

Takeshima T, Sakai F, Wang X, Yamato K, Kojima Y, Zhang Y et al (2024) Cost effectiveness of Fremanezumab in episodic and chronic migraine patients from a Japanese healthcare perspective. Pharmacoeconomics 42(7):811–822. https://doi.org/10.1007/s40273-024-01380-0

Article  PubMed  PubMed Central  Google Scholar 

Wolters S, Carpay JA, Pronk MH, Zuurbier KWM, Driessen MT, Lyras L et al (2024) A Dutch cost-effectiveness analysis of fremanezumab versus best supportive care in patients with chronic migraine and inadequate response to prior preventive therapy. BMC Neurol 24(1):1–12

Google Scholar 

Mahon R, Lang A, Vo P, Huels J, Cooney P, Danyliv A et al (2021) Cost-effectiveness of erenumab for the preventive treatment of migraine in patients with prior treatment failures in Sweden. Pharmacoeconomics 39(3):357–372. https://doi.org/10.1007/s40273-020-00996-2

Article  PubMed  Google Scholar 

Hansson-Hedblom A, Axelsson I, Jacobson L, Tedroff J, Borgström F (2020) Economic consequences of migraine in Sweden and implications for the cost-effectiveness of onabotulinumtoxinA (Botox) for chronic migraine in Sweden and Norway. J Headache Pain 21(1):1–15

Google Scholar 

Giannouchos TV, Mitsikostas DD, Ohsfeldt RL, Vozikis A, Koufopoulou P (2019) Cost-effectiveness analysis of erenumab versus onabotulinumtoxina for patients with chronic migraine attacks in Greece. Clin Drug Investig 39(10):979–990. https://doi.org/10.1007/s40261-019-00827-z

Article  PubMed  Google Scholar 

Shauly O, Gould DJ, Patel KM (2018) cost utility analysis of surgical decompression relative to injection therapy for chronic migraine headaches. Aesthetic Surg J. 2018;(January):2010–7

Schoenbrunner AR, Khansa I, Janis JE (2020) Cost-effectiveness of long-term, targeted OnabotulinumtoxinA versus Peripheral trigger site deactivation surgery for the treatment of refractory migraine headaches. Plast Reconstr Surg 145(2):401e–406e

CAS  PubMed  Google Scholar 

Hollier-Hann G, Curry A, Onishchenko K, Akehurst R, Ahmed F, Davies B et al (2020) Updated cost-effectiveness analysis of onabotulinumtoxinA for the prevention of headache in adults with chronic migraine who have previously received three or more preventive treatments in the UK. J Med Econ 23(1):113–123. https://doi.org/10.1080/13696998.2019.1675417

Article  PubMed  Google Scholar 

Vekov T, Izmaylov A (2020) Cost-effectiveness analysis of CGRP inhibitors for treatment of patients with chronic or episodic migraine. Gen Med 21(5):33–38

Google Scholar 

Lipton RB, Brennan A, Palmer S, Hatswell AJ, Porter JK, Sapra S et al (2018) Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. J Med Econ 21(7):666–675. https://doi.org/10.1080/13696998.2018.1457533

Article  PubMed  Google Scholar 

Sussman M, Benner J, Neumann P, Menzin J (2018) Cost-effectiveness analysis of erenumab for the preventive treatment of episodic and chronic migraine: results from the US societal and payer perspectives. Cephalalgia 38(10):1644–1657

PubMed  Google Scholar 

Messali A, Sanderson JC, Blumenfeld AM, Goadsby PJ, Buse DC, Varon SF et al (2016) Direct and indirect costs of chronic and episodic migraine in the United States: a web-based survey. Headache 56(2):306–22. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-84958883794&doi=10.1111%2Fhead.12755&partnerID=40&md5=2c179a88c257fd3d2a0785b365732c89. Accessed 10 Apr 2025

Badia X, Magaz S, Gutiérrez L, Galván J (2004) The burden of migraine in Spain: beyond direct costs. Pharmacoeconomics 22(9):591–603. Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0-3242727841anddoi=10.2165%2F00019053-200422090-00004andpartnerID=40andmd5=c7cd1ae0fc1eab88a11563ca425cb6e7. Accessed 10 Apr 2025

Dodick DW, Reed ML, Lee L, Balkaran BL, Umashankar K, Parikh M et al (2024) Impact of headache frequency and preventive treatment failure on quality of life, disability, and direct and indirect costs among individuals with episodic migraine in the United States. Headache 64(4):361–373

PubMed  Google Scholar 

García-Azorín D, Moya-Alarcón C, Armada B, Sánchez del Río M (2024) Societal and economic burden of migraine in Spain: results from the 2020 National Health and Wellness Survey. J Headache Pain 25(1):1–12. https://doi.org/10.1186/s10194-024-01740-3

Sun W, Cheng H, Xia B, Liu X, Li Y, Wang X et al (2023) Comparative efficacy and safety of five anti-calcitonin gene-related peptide agents for migraine prevention: a network meta-analysis. Clin J Pain 39(10):560–569

PubMed  Google Scholar 

Lampl C, MaassenVanDenBrink A, Deligianni CI, Gil-Gouveia R, Jassal T, Sanchez-del-Rio M, et al (2023) The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis. J Headache Pain [Internet] 24(1):1–14. https://doi.org/10.1186/s10194-023-01594-1

Mohammadnezhad G, Assarzadegan F, Koosha M, Esmaily H (2025) Eicosapentaenoic acid versus placebo as adjunctive therapy in chronic migraine: a randomized controlled trial. Headache 65:153–163. https://doi.org/10.1111/head.14808

Article  PubMed  Google Scholar